Advaxis’ (ADXS) Buy Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reiterated their buy rating on shares of Advaxis, Inc. (NASDAQ:ADXS) in a research report report published on Monday. The brokerage currently has a $19.00 price objective on the biotechnology company’s stock.
“Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda.”,” Cantor Fitzgerald’s analyst commented.
Several other equities research analysts have also recently commented on ADXS. BidaskClub cut Advaxis from a hold rating to a sell rating in a research note on Monday, July 31st. ValuEngine lowered Advaxis from a sell rating to a strong sell rating in a research report on Tuesday, August 8th. Finally, HC Wainwright restated a buy rating and issued a $23.00 price target on shares of Advaxis in a research report on Friday, September 15th.
Shares of Advaxis (ADXS) opened at 4.49 on Monday. The stock’s 50 day moving average price is $6.19 and its 200 day moving average price is $7.33. The stock’s market capitalization is $184.38 million. Advaxis has a one year low of $3.91 and a one year high of $12.66.
Advaxis (NASDAQ:ADXS) last released its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. On average, analysts forecast that Advaxis will post ($2.23) EPS for the current year.
In other news, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the firm’s stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $4.42, for a total value of $5,477,807.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. 7.21% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the company. Stevens Capital Management LP bought a new position in shares of Advaxis in the 1st quarter worth $105,000. Voya Investment Management LLC boosted its position in shares of Advaxis by 20.3% in the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 2,975 shares during the last quarter. Cutler Capital Management LLC bought a new position in shares of Advaxis in the 2nd quarter worth $130,000. American International Group Inc. boosted its position in shares of Advaxis by 7.6% in the 1st quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 1,459 shares during the last quarter. Finally, Northern Capital Management LLC boosted its position in shares of Advaxis by 14.6% in the 2nd quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 2,650 shares during the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.